Phase 3 study results demonstrate efficacy and safety of the calcimimetic cinacalcet HCI in hemodialysis patients with secondary hyperparathyroidism (HPT).

被引：0

作者：

Block, GA

Martin, KJ

Turner, SA

Avram, MM

Hercz, G

Abu-Alfa, AK

Coyne, DW

Cohen, RM

Moe, SM

McCary, LC

Olson, KA

Goodman, WG

机构：

[1] Denver Nephrol, Denver, CO USA

[2] St Louis Univ, St Louis, MO 63103 USA

[3] Amgen Inc, Nephrol, Thousand Oaks, CA 91320 USA

[4] Long Isl Coll Hosp, Brooklyn, NY 11201 USA

[5] Humber River Reg Hosp, Toronto, ON, Canada

[6] Yale Univ, Sch Med, New Haven, CT USA

[7] Washington Univ, Sch Med, St Louis, MO USA

[8] Presbyterian Med Ctr, Philadelphia, PA 19104 USA

[9] Indiana Univ, Sch Med, Indianapolis, IN 46204 USA

[10] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA

来源：

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2003年 / 14卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：461A / 461A

页数：1